Description
Xynomic Pharmaceuticals Holdings, Inc. a biopharmaceutical company, focuses on in-licensing, developing, and commercializing oncology drug candidates in China, the United States, and internationally. The company's pipeline primarily consists of three drug candidates, abexinostat, XP-105, and XP-102. Its lead drug candidate abexinostat is in pivotal clinical trials against renal cell carcinoma (in combination with pazopanib) and non-Hodgkin's lymphoma (as a single agent). The company's other clinical stage drug candidate XP-105 (BI 860585) is a Phase 2 ready, ATP-competitive mTORC1/2 inhibitor against solid tumors; and pre-clinical oncology drug candidate XP-102 (BI 882370) is a pan-RAF inhibitor. The company was founded in 2016 and is headquartered in Shanghai, China.
